For the last several years, the life sciences industry has been fertile ground for class action and aggregate litigation. Developments in this area have driven several trends, including state consumer fraud claims, securities class actions, antitrust class actions, and aggregate litigation brought by private healthcare insurers and state attorneys general. These recent trends have been driven, in part, by legislative and doctrinal developments. For example, in 2005 — based on legislative findings of abuse in class action practice in state courts — Congress enacted the Class Action Fairness Act (CAFA), permitting defendants to remove to federal court putative class actions that previously may have been subject to less stringent standards in state court. In Standard Fire Insurance Co. v. Knowles, the U.S. Supreme Court held that a plaintiff’s stipulation that he would not accept more than $5 million in damages could not be used to avoid CAFA’s amount in controversy requirement. In other words, a class representative may not agree to seek less money to try to keep a case in state court.
Recent U.S. Supreme Court decisions have also significantly shaped class action practice. The Supreme Court’s decision in Wal-Mart Stores, Inc. v. Dukes established that claims for individual money damages may be certified under Federal Rule of Civil Procedure (FRCP) 23(b)(2) in only limited circumstances, and the Court’s decision also announced a more restrictive view of the meaning of a “common question” under FRCP 23(a). Most recently, in Comcast Corp. v. Behrend, the Court held that plaintiffs seeking class certification in antitrust cases must tie their theory of harm and damages to their liability theory, and, in appropriate circumstances, individual questions of damages can predominate over liability issues common to the class.
Please see full alert below for more information.
Firefox recommends the PDF Plugin for Mac OS X for viewing PDF documents in your browser.
We can also show you Legal Updates using the Google Viewer; however, you will need to be logged into Google Docs to view them.
Please choose one of the above to proceed!
LOADING PDF: If there are any problems, click here to download the file.
Topics: Aggregation Rules, Antitrust Litigation, Class Action, Fraud, Life Sciences, Securities Litigation
Published In: Antitrust & Trade Regulation Updates, Business Torts Updates, Consumer Protection Updates, Products Liability Updates, Science, Computers & Technology Updates
DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.
© Morgan Lewis | Attorney Advertising